OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
603260$40.6358

603260.SS

Specialty ChemicalsVerified

The company's capital structure shows a debt-to-equity ratio of 1.13, indicating moderate leverage. With a current ratio of 0.33, the company faces liquidity constraints, as current assets significantly lag behind current liabilities. The price-to-book ratio of 1.64 suggests the market values the company at a premium to its book value, but this is partially offset by negative returns on equity (-10.23%) and assets (-3.58%). Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of CNY 2.99 billion and operating loss of CNY 2.63 billion, with a gross profit of only CNY 1.08 billion on CNY 20.5 billion in revenue. These results indicate operational inefficiencies and pricing pressures in the specialty chemicals market. Geographic and segment exposure data is not available in the provided dataset. However, the company's revenue concentration in a single business line (specialty chemicals) creates operational risk if demand for chemical products declines in key markets. Growth trajectory analysis shows negative momentum. The company's free cash flow is negative at CNY -1.87 billion, and operating cash flow of CNY 4.01 billion is insufficient to cover capital expenditures of CNY 1.19 billion. With a price target range of CNY 52.62 to CNY 55.00, analysts expect a 27-33% price appreciation from current levels. Risk factors include liquidity constraints (current ratio of 0.33) and negative net cash position after debt. The company has low dilution risk with basic and diluted shares outstanding aligned at 1.18 billion shares. No material dilution adjustments were applied in valuation models. Recent filings show deteriorating profitability with consecutive losses in operating and net income. The company's capital expenditure of CNY 1.19 billion indicates ongoing investment in production capacity, but this is not offsetting declining margins.

30-day price · 603260-4.68 (-10.5%)
Low$38.81High$46.77Close$40.02As of28 May, 00:00 UTC
Profile
Company603260.SS
Ticker603260.SS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. The company operates in the specialty chemicals industry, producing and selling chemical products for industrial applications.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with 92% confidence.

The company's capital structure shows a debt-to-equity ratio of 1.13, indicating moderate leverage. With a current ratio of 0.33, the company faces liquidity constraints, as current assets significantly lag behind current liabilities. The price-to-book ratio of 1.64 suggests the market values the company at a premium to its book value, but this is partially offset by negative returns on equity (-10.23%) and assets (-3.58%). Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of CNY 2.99 billion and operating loss of CNY 2.63 billion, with a gross profit of only CNY 1.08 billion on CNY 20.5 billion in revenue. These results indicate operational inefficiencies and pricing pressures in the specialty chemicals market. Geographic and segment exposure data is not available in the provided dataset. However, the company's revenue concentration in a single business line (specialty chemicals) creates operational risk if demand for chemical products declines in key markets. Growth trajectory analysis shows negative momentum. The company's free cash flow is negative at CNY -1.87 billion, and operating cash flow of CNY 4.01 billion is insufficient to cover capital expenditures of CNY 1.19 billion. With a price target range of CNY 52.62 to CNY 55.00, analysts expect a 27-33% price appreciation from current levels. Risk factors include liquidity constraints (current ratio of 0.33) and negative net cash position after debt. The company has low dilution risk with basic and diluted shares outstanding aligned at 1.18 billion shares. No material dilution adjustments were applied in valuation models. Recent filings show deteriorating profitability with consecutive losses in operating and net income. The company's capital expenditure of CNY 1.19 billion indicates ongoing investment in production capacity, but this is not offsetting declining margins.
Key takeaways
  • The company has a debt-to-equity ratio of 1.13 with liquidity constraints (current ratio of 0.33)
  • Negative returns on equity (-10.23%) and assets (-3.58%) indicate operational underperformance
  • Analysts expect 27-33% price appreciation despite current losses
  • Free cash flow is negative at CNY -1.87 billion with operating cash flow insufficient to cover capital expenditures
  • The company has low dilution risk with aligned basic and diluted share counts
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "Margins are expected to remain under pressure due to negative operating and net income trends",
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$20.50B
Gross profit$1.08B
Operating income-$2.63B
Net income-$2.99B
R&D
SG&A
D&A
SBC
Operating cash flow$4.01B
CapEx-$1.19B
Free cash flow-$1.87B
Total assets$83.61B
Total liabilities$54.36B
Total equity$29.25B
Cash & equivalents
Long-term debt$32.92B
Valuation
Market price$40.63
Market cap$48.03B
Enterprise value$80.95B
P/E
Reported non-GAAP P/E
EV/Revenue4.0
EV/Op income
EV/OCF20.2
P/B1.6
P/Tangible book1.6
Tangible book$29.25B
Net cash-$32.92B
Current ratio0.3
Debt/Equity1.1
ROA-3.6%
ROE-10.2%
Cash conversion-1.3%
CapEx/Revenue-5.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
Metric603260Activity
Op margin-12.8%5.5% medp25 -0.0% · p75 10.8%bottom quartile
Net margin-14.6%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin5.3%20.5% medp25 12.4% · p75 29.7%bottom quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-5.8%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity113.0%37.1% medp25 10.3% · p75 82.0%top quartile
Observations
IR observations
Mean price target53.81 CNY
Median price target53.81 CNY
High price target55.00 CNY
Low price target52.62 CNY
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.07 CNY
Last actual EPS-2.55 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 14:17 UTC#7962a48e
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 00:57 UTCJob: 6b7a1650